HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $30

Benzinga Newsdesk www.benzinga.com Neutral 63.1%

Neg 0% Neu 63.1% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $45 to $30.